Jan 27 (Reuters) - Akero Therapeutics AKRO.O shares gained 106% before the bell on Monday after the company reported results from a mid-stage trial studying its lead drug in patients with a type of liver disease.
The experimental drug efruxifermin is being studied in patients with scarring due to a type of fatty liver disease known as metabolic dysfunction-associated steatohepatitis.
(Reporting by Sriparna Roy in Bengaluru; Editing by Krishna Chandra Eluri)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.